Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pegasus' DermADAPT dressing:

This article was originally published in Clinica

Executive Summary

Advanced biologic scaffolds maker Pegasus Biologics has entered the wound care market, after receiving US FDA 510(k) market clearance for its collagen-based DermADAPT biomatrix dressing. Approved for the local management of moderate to heavy exuding wounds, the product will be initially targeted to the diabetic foot ulcer market; in the US alone, five million diabetic patients suffer from foot ulcers, according to the privately held, Irvine, California firm. DermADAPT is strong and stable, maintaining an ideal environment for wound healing, said the company. It is also thin and pliable, and conforms well to the wound bed. Pegasus already sells a product for repairing ligaments and tendons, OrthADAPT bioimplant.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT053432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel